# US 2025/0367154 A1 · Formulations for promoting hydration and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367154 A1
- Document ID: US20250367154A1
- Status: Published application
- Kind: A1
- Application number: 19/233,780
- Filed: 2025-06-10
- Published: 2025-12-04
- Earliest claimed: 2020-07-02
- Assignees: University of Florida Research Foundation, Inc.; AmiLyfe, LLC
- Applicants: University of Florida Research Foundation, Incorporated; Amilyfe, LLC
- Inventors: Sadasivan VIDYASAGAR; Astrid GROSCHE; Xiaodong XU; Shanshan LIN; Samuel CHEUVRONT; Robert KENEFICK; Stephen GATTO
- Web page: https://patentgrep.com/patent/US20250367154A1

## CPC

- A23L 2/52: Adding ingredients (adding preservatives A23B70/10)
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Formulations comprising particular free amino acids useful for promoting hydration and/or intestinal barrier function in a subject in need thereof are described herein. Such formulations and methods using same are useful for promoting hydration and/or intestinal barrier function in a subject in need thereof. Such subjects may be healthy, but in need of a formulation that promotes rapid hydration (e.g., within 15-90 minutes post-administration) or promotes intestinal barrier function; or such subjects may be afflicted by a disorder or disease associated with dehydration or impaired intestinal barrier function, respectively. Use of amino acid formulations described herein for promoting hydration and/or intestinal barrier function in a subject in need thereof, for the treatment of disorders or diseases associated dehydration and/or impaired intestinal barrier function, and in the preparation of a medicament for the treatment of disorders or diseases associated with dehydration and/or impaired intestinal barrier function are encompassed herein.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method for promoting hydration in a subject in need thereof, the method comprising:
administering to the subject a formulation comprising:
a therapeutically effective combination of free amino acids consisting essentially of aspartic acid, isoleucine, serine, threonine, tyrosine, and valine,
wherein the molar ratio of aspartic acid/isoleucine ranges from 5.5 aspartic acid/1 isoleucine to 1.5 aspartic acid/1 isoleucine,
wherein the molar ratio of aspartic acid/serine ranges from 2.8 aspartic acid/1 serine to 1 aspartic acid/1 serine,
wherein the molar ratio of aspartic acid/threonine ranges from 5.5 aspartic acid/1 threonine to 1.3 aspartic acid/1 threonine,
wherein the molar ratio of aspartic acid/tyrosine ranges from 40 aspartic acid/1 tyrosine to 9 aspartic acid/1 tyrosine,
wherein the molar ratio of aspartic acid/valine ranges from 3.8 aspartic acid/1 valine to 1.4 aspartic acid/1 valine;
and
at least one electrolyte,
wherein the formulation is substantially free of carbohydrates,
whereby administrating promotes hydration in the subject relative to a formulation without the therapeutically effective combination of free amino acids.

### Claim 22 (depends on 21)

The method of claim 21, wherein the at least one electrolyte comprises 17 mM-140 mM sodium.

### Claim 23 (depends on 21)

The method of claim 21, wherein a total weight percent of aspartic acid and serine is greater than a total weight percent of isoleucine, threonine, tyrosine, and valine.

### Claim 24 (depends on 21)

The method of claim 21, wherein each of the free amino acids has a concentration ranging from 0.1 mM-30 mM.

### Claim 25 (depends on 21)

The method of claim 21, wherein a concentration of aspartic acid ranges from 0.1 mM-5 mM.

### Claim 26 (depends on 21)

The method of claim 21, wherein the therapeutically effective combination of free amino acids is sufficient to promote fluid absorption or intestinal barrier integrity, thereby promoting hydration or intestinal barrier function in the subject.

### Claim 27 (depends on 26)

The method of claim 26, wherein the promoted fluid absorption reflects an increased rate of fluid absorption in the subject.

### Claim 28 (depends on 27)

The method of claim 27, wherein the increased rate of fluid absorption comprises a relative increase of at least 15%.

### Claim 29 (depends on 21)

The method of claim 21, wherein the formulation without the therapeutically effective combination of free amino acids comprises carbohydrates or is sugar-free.

### Claim 30 (depends on 21)

The method of claim 21, wherein the subject is a healthy subject suffering from electrolyte loss, dehydration, or heat stress.

### Claim 31 (depends on 21)

The method of claim 21, wherein the subject is a subject suffering from a disease or disorder associated with dehydration, or symptoms thereof.

### Claim 32 (depends on 21)

The method of claim 21, wherein the subject is a subject suffering from a disease or disorder associated with impaired intestinal barrier function.

### Claim 33 (depends on 26)

The method of claim 26, wherein the promoted intestinal barrier integrity reflects at least one of a reduction in intestinal permeability; an increase in E-cadherin expression and/or activity; and increase in occludin protein expression and/or activity; a decrease in claudin-2 protein expression and/or function; or any combination thereof.

### Claim 34 (depends on 21)

The method of claim 21, wherein administering is by an enteral route.

### Claim 35 (depends on 34)

The method of claim 34, wherein administering by an oral route.

### Claim 36 (depends on 21)

The method of claim 21, wherein a total weight percent of free amino acids of aspartic acid ranges from 30% to 55% of a total weight of the therapeutically effective combination of free amino acids.

### Claim 37 (depends on 21)

The method of claim 21, wherein the formulation comprises at least one pharmaceutically acceptable carrier, buffer, adjuvant, excipient, or any combination thereof.

### Claim 38 (depends on 21)

The method of claim 21, wherein the formulation comprises water.

### Claim 39 (depends on 21)

The method of claim 21, wherein at least one of the free amino acids is an L-amino acid.

### Claim 40 (depends on 21)

The method of claim 21, wherein each of the free amino acids is an L-amino acid.
